Abstract:Liquid biopsy methodologies, for the purpose of plasma genotyping of cell-free DNA (cfDNA) of solid tumors, are a new class of novel molecular assays. Such assays are rapidly entering the clinical sphere of research-based monitoring in translational oncology, especially for thoracic malignancies. Potential applications for these blood-based cfDNA assays include: (i) initial diagnosis, (ii) response to therapy and follow-up, (iii) tumor evolution, and (iv) minimal residual disease evaluation. Precision medicine will benefit from cutting-edge molecular diagnostics, especially regarding treatment decisions in the adjuvant setting, where avoiding over-treatment and unnecessary toxicity are paramount. The use of innovative genetic analysis techniques on individual patient tumor samples is being pursued in several advanced clinical trials. Rather than using a categorical treatment plan, the next critical step of therapeutic decision making is providing the "right" cancer therapy for an individual patient, including correct dose and timeframe based on the molecular analysis of the tumor in question. Per the 21st Century Cures Act, innovative clinical trials are integral for biomarker and drug development. This will include advanced clinical trials utilizing: (i) innovative assays, (ii) molecular profiling with cutting-edge bioinformatics, and (iii) clinically relevant animal or tissue models. In this paper, a mini-review addresses state-of-the-art liquid biopsy approaches. Additionally, an on-going advanced clinical trial for lung cancer with novelty through synergizing liquid biopsies, co-clinical trials, and advanced bioinformatics is also presented. Impact statement Liquid biopsy technology is providing a new source for cancer biomarkers, and adds new dimensions in advanced clinical trials. Utilizing a non-invasive routine blood draw, the liquid biopsy provides abilities to address perplexing issues of tumor tissue heterogeneity by identifying mutations in both primary and metastatic lesions. Regarding the assessment of response to cancer therapy, the liquid biopsy is not ready to replace medical imaging, but adds critical new information; for instance, through a temporal assessment of quantitative circulating tumor DNA (ctDNA) assay results, and importantly, the ability to monitor for signs of resistance, via emerging clones. Adjuvant therapy may soon be considered based on a quantitative cfDNA assay. As sensitivity and specificity of the technology continue to progress, cancer screening and prevention will improve and save countless lives by finding the cancer early, so that a routine surgery may be all that is required for a definitive cure.

Liquid biopsy as a new era in endometrial cancer

Liquid Biopsy in Endometrial Cancer: New Opportunities for Personalized Oncology

Diagnostic Accuracy of Liquid Biopsy in Endometrial Cancer

Liquid biopsy: paving a new avenue for cancer research

The functional and clinical roles of liquid biopsy in patient-derived models

Liquid Biopsy: A New, Non-Invasive Early Diagnostic and Prognostic Tool in Oncology

Liquid biopsy in breast cancer: A comprehensive review

Liquid Biopsy in Clinical Management of Breast, Lung, and Colorectal Cancer

Liquid biopsy: current technology and clinical applications

Abstract A012: Genomic landscape of somatic alterations identified in endometrial cancer using liquid biopsy

The Liquid Biopsy Consortium: Challenges and Opportunities for Early Cancer Detection and Monitoring

Circulating Cell-Free DNA or Circulating Tumor DNA in the Management of Ovarian and Endometrial Cancer

Liquid biopsy and its role in an advanced clinical trial for lung cancer

Liquid Biopsies, Novel Approaches and Future Directions

LIQUID BIOPSY: A NON-INVASIVE TOOL TO DETECT CANCER AT AN EARLY STAGE

Liquid biopsy, an innovation of modern medicine

Circulating tumor DNA as a prognostic marker in high-risk endometrial cancer

Biomarkers of Lung Cancer: Liquid Biopsy Comes of Age

Liquid Biopsy in the Clinical Management of Cancers

Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments